The Inhibitory Effect of DLX4 RNAi on Adhesion and Invasion Ability of Choriocarcinoma Cells

Feng Yan

2007-01-01

Abstract:Background and purpose:Choriocarcinoma is a highly malignant tumor,which metastasis could occur at early stage,the molecular mechanism is still under investigation.DLX4 is a member of homeodomain transcriptional factors,and its abnormal expression has a close correlation with mammary cancer,colon caner and so on.Based on our previous study that DLX4 was highly expressed in choriocarcinoma JEG-3 cell lines,we used RNAi to knock down the expression of DLX4,and aimed to explore the effect of DLX4 on the adhesion,movement and invasion ability of choriocarcinoma cells.Methods:DLX4 siRNA and control siRNA plasmid were constructed and transfected into choriocarcinoma cell line JEG-3 cells with LipofectamineTM2000.JEG-3 cells that expressed high level of DLX4 siRNA and control siRNA plasmid were selected and maintained with G418.The effect of RNAi was detected by western blot,and then the adhesion,movement and invasion ability of JEG-3 cells were investigated by cell-ECM adhesion assay,Transwell chamber and Transwell-Matrigel model,respectively.Results:DLX4 RNAi inhibited DLX4 protein expression specifically and effectively.The adhesion rate of the cells in JEG-3 siDLX4 group was(30.6±4.2)%,which was significantly less than(57.2±4.0)% in JEG-3 without transfenction and(51.6±3.9)% in JEG-3 scDLX4 groups(P0.01 and P0.05,respectively).The movement and invasion ability were evidently inhibited in JEG-3 siDLX4 group compared with those in JEG-3 non-transfenction and JEG-3 scDLX4 groups [(31±3),(21±4)/HP vs.(68±5),(64±4)/HP and(70±4),(67±5)/HP,respectively,P0.01],while the adhesion,movement and invasion ability of the cells between JEG-3 non-transfenction and JEG-3 scDLX4 groups were not different(all of P0.05).Conclusions:The knock-down of DLX4 by RNAi could prevent the adhesion and invasion ability of choriocarcinoma cells,which provides a new thought for further research in invasion and metastasis of choriocarcinoma.